Thomas A Waldmann Selected Research

Interleukin-6 (Interleukin 6)

1/2018	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
11/2017	Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas A Waldmann Research Topics

Disease

91	Neoplasms (Cancer) 10/2022 - 02/2002
32	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 10/2022 - 02/2002
27	Lymphoma (Lymphomas) 01/2021 - 02/2002
19	Leukemia 10/2019 - 02/2002
12	T-Cell Leukemia (Leukemia, T Cell) 01/2017 - 02/2002
11	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2003
8	Infections 01/2021 - 11/2007
8	Multiple Sclerosis 10/2019 - 06/2004
7	T-Cell Lymphoma (Lymphoma, T Cell) 01/2021 - 02/2002
7	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 10/2015
6	Celiac Disease (Celiac Sprue) 01/2020 - 01/2006
6	Melanoma (Melanoma, Malignant) 01/2019 - 01/2014
6	Inflammation (Inflammations) 11/2014 - 09/2008
6	Vaccinia 04/2014 - 03/2003
5	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 06/2012
4	Uveitis 01/2019 - 11/2003
4	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 11/2017 - 12/2003
4	Rheumatoid Arthritis 10/2015 - 09/2005
4	Breast Neoplasms (Breast Cancer) 11/2014 - 05/2004
4	Smallpox (Variola) 10/2010 - 01/2007
3	Hematologic Neoplasms (Hematological Malignancy) 10/2019 - 11/2005
3	Large Granular Lymphocytic Leukemia 01/2019 - 01/2006
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2019 - 01/2015
3	Human Influenza (Influenza) 01/2018 - 07/2005
3	Carcinoma (Carcinomatosis) 12/2010 - 01/2005
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2020 - 10/2015
2	Kidney Neoplasms (Kidney Cancer) 01/2020 - 12/2018
2	Atrophy 01/2020 - 09/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 01/2006
2	Hairy Cell Leukemia 12/2018 - 11/2004
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 12/2003
2	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2013 - 01/2007
2	Disease Progression 10/2011 - 04/2009
2	Encephalitis (Encephalitis, Rasmussen) 05/2011 - 04/2006

Drug/Important Bio-Agent (IBA)

57	Interleukin-15 (Interleukin 15)IBA 04/2022 - 01/2003
32	Monoclonal AntibodiesIBA 01/2022 - 02/2002
25	CytokinesIBA 01/2021 - 01/2006
19	Interleukin-2 (IL2)IBA 01/2021 - 03/2002
18	VaccinesIBA 01/2019 - 03/2003
15	AntibodiesIBA 01/2022 - 08/2004
13	Daclizumab (Zenapax)FDA Link 05/2020 - 11/2003
11	Alemtuzumab (Campath)FDA Link 04/2022 - 10/2003
10	AntigensIBA 05/2020 - 01/2006
8	Proteins (Proteins, Gene)FDA Link 11/2020 - 06/2002
8	Interleukin-2 Receptors (IL 2 Receptor)IBA 11/2018 - 02/2002
7	Pharmaceutical PreparationsIBA 12/2022 - 11/2004
4	Phosphotransferases (Kinase)IBA 11/2020 - 01/2017
4	Interleukin-9 (Interleukin 9)IBA 01/2020 - 05/2008
4	Rituximab (Mabthera)FDA Link 01/2020 - 04/2008
4	Radioisotopes (Radionuclides)IBA 02/2008 - 07/2002
4	Interleukin-2 Receptor alpha SubunitIBA 08/2006 - 07/2002
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2020 - 02/2004
3	Immune Checkpoint InhibitorsIBA 10/2019 - 12/2015
3	siplizumabIBA 01/2018 - 07/2003
3	Cytokine Receptors (Cytokine Receptor)IBA 11/2017 - 12/2013
3	Janus Kinase InhibitorsIBA 11/2017 - 04/2013
3	navitoclaxIBA 01/2017 - 10/2015
3	tofacitinibIBA 10/2015 - 02/2011
3	Glycoproteins (Glycoprotein)IBA 12/2014 - 02/2002
3	DNA VaccinesIBA 11/2014 - 07/2005
3	Therapeutic UsesIBA 03/2012 - 05/2004
3	Fc Receptors (Fc Receptor)IBA 07/2006 - 10/2003
3	Dendrimers (Dendrons)IBA 11/2005 - 04/2004
3	Contrast MediaIBA 11/2004 - 04/2004
2	Mechanistic Target of Rapamycin Complex 1IBA 10/2022 - 01/2021
2	Trans-Activators (Trans-Acting Factor)IBA 01/2021 - 10/2015
2	LigandsIBA 01/2021 - 01/2020
2	obinutuzumabIBA 01/2021 - 01/2020
2	Small Interfering RNA (siRNA)IBA 01/2021 - 04/2016
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2018
2	avelumabIBA 01/2021 - 01/2020
2	UbiquitinIBA 11/2020 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 05/2020 - 01/2019
2	Brentuximab VedotinIBA 01/2020 - 02/2016
2	NivolumabIBA 01/2020 - 10/2019
2	InterleukinsIBA 01/2020 - 12/2018
2	IpilimumabIBA 01/2020 - 02/2007
2	interleukin-21 (interleukin 21)IBA 01/2020 - 11/2015
2	DNA (Deoxyribonucleic Acid)IBA 06/2019 - 04/2016
2	NF-kappa B (NF-kB)IBA 06/2019 - 02/2002
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 01/2016
2	InterferonsIBA 12/2018 - 06/2012
2	Interleukin-6 (Interleukin 6)IBA 01/2018 - 11/2017
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 12/2010
2	Anaplastic Lymphoma KinaseIBA 11/2017 - 11/2004
2	ruxolitinibIBA 02/2016 - 10/2015
2	Membrane Proteins (Integral Membrane Proteins)IBA 12/2014 - 09/2007
2	LipidsIBA 12/2014 - 07/2004
2	Influenza Vaccines (Influenza Vaccine)FDA Link 04/2014 - 03/2009
2	Glutens (Glutelin)IBA 04/2013 - 09/2009
2	B7-H1 AntigenIBA 04/2012 - 12/2010
2	Neoplasm Antigens (Tumor Antigens)IBA 04/2012 - 07/2005
2	CTLA-4 AntigenIBA 04/2012 - 12/2010

Therapy/Procedure

48	Therapeutics 12/2022 - 10/2002
16	Immunotherapy 01/2022 - 07/2002
6	Drug Therapy (Chemotherapy) 01/2021 - 10/2011
6	Radioimmunotherapy 06/2009 - 07/2002
3	Intravenous Infusions 01/2019 - 12/2014
3	Radiotherapy 08/2012 - 02/2003
2	Immunomodulation 01/2019 - 01/2006